RE: [NMusers] ASCO and pharmacometrics

From: Naoto Hayashi <neohayashi_at_gmail.com>
Date: Wed, 6 Apr 2016 18:01:21 +0900

Dear Pascal,

How are you doing? Thanks for your reply.

The first author was an oncologist although its content was mainly a model
work. Therefore, readability for oncologist would be OK.

Can I understand as Rene is the only one champion to present a poster in
ASCO for pharmacometrics? It is so shocking to me.

I wanted to know that ASCO does not like model work so much.

Just one lucky thing was that it was not reject and allowed to be online
publication.

However, rejection of poster presentation is my first experience.

Depressed.

Best regards,
Naoto
2016/04/06 17:39 "Pascal Girard" <pascal.girard_at_merckgroup.com>:

> Dear Naoto,
>
>
>
> In the past, Rene Bruno got one poster accepted with discussion at ASCO.
> He is our ”champion” !
>
>
>
> I got one accepted on model for Exp-Tumor Size – OS at European C=
ancer
> Congress 2013 . But I can tell you that a medical writer rewrote it
> entirely and it took 1 month to get it reviewed and corrected by clinicia=
ns
> challenging every comma and p-value.
>
>
>
> To give you an idea of the respective size of the meetings: ACOP N=500,
> PAGE N>600, ECC N> 10,000, ASCO N>20,000.
>
>
>
> So the advice I would give, is just improve the quality and readability o=
f
> our abstract and it will meke it. By readability, I mean show it to an
> oncologist clinician. If he does not understand, rewrite it with the help
> of a medical writer …
>
>
>
> *With best regards / Mit freundlichen Grüßen / Cordialement*
>
>
>
> Pascal
>
>
>
> *Vacation*
>
> 7 April
>
>
>
>
>
> *From:* owner-nmusers_at_globomaxnm.com [mailto:owner-nmusers_at_globomaxnm.com=
]
> *On Behalf Of *Naoto Hayashi
> *Sent:* 06 April 2016 09:46
> *To:* jgrevel_at_btconnect.com
> *Cc:* nmusers <nmusers_at_globomaxnm.com>
> *Subject:* Re: [NMusers] ASCO and pharmacometrics
>
>
>
> Dear Joachim,
>
>
>
> Thank you so much for your reply.
>
>
>
> Their abstract instruction allows very small number of characters, and no
> enough room to express what we had established in this work.
>
>
>
> Although we described the unique results in the table, they probably coul=
d
> not understand its meaning, or the model's outcome that I was so excited
> has no meaning to oncologist.
>
>
>
> It seemed so nice work for me and I hope that US pharmacometrician societ=
y
> would communicate with ASCO people for our future.
>
>
>
> Thanks!
>
>
>
> Best regards,
>
> Naoto Hayashi, PhD
>
>
>
>
>
> 2016-04-06 15:58 GMT+09:00 Joachim Grevel <jgrevel_at_btconnect.com>:
>
> Dear Naoto,
>
> Your experience is also mine. For a combined TTE safety and efficacy
> analysis I earned the online publication. The organisers do not believe i=
n
> modelling, unless it describes what is already visible in graphs and tabl=
es
> of raw data.
>
> This is just my personal impression. I have not been to ASCO either.
>
>
>
> Good luck,
>
> Joachim
>
>
>
>
>
> *Joachim Grevel, PhD*
>
> Scientific Director
>
> BAST Inc Limited
>
> Science & Enterprise Park
>
> Loughborough University
>
> Loughborough, LE11 3AQ
>
> United Kingdom
>
>
>
> Tel: +44 (0)1509 222908
>
> www.bastinc.eu
>
>
>
>
>
>
>
> *From:* owner-nmusers_at_globomaxnm.com [mailto:owner-nmusers_at_globomaxnm.com=
]
> *On Behalf Of *Naoto Hayashi
> *Sent:* 06 April 2016 02:38
> *To:* nmusers_at_globomaxnm.com
> *Subject:* [NMusers] ASCO and pharmacometrics
>
>
>
>
>
> Dear all,
>
>
>
> I have a question and appreciate it if somebody can answer to me.
>
>
>
> We had submitted an abstract to ASCO annual meeting presentation 2016, an=
d
> its contents included a pharmacometrics work of quantitative safety profi=
le
> analysis of an anticancer drug. The behave of the safety index time
> courses is very unique and its results showed a very high usefulness of
> this drug. The abstract also included the table of population PK/PD
> parameters that expressed its nature, and it was compared with the simila=
r
> older drug safety profile and demonstrated very high safer profile
> quantitatively.
>
>
>
> I have some experiences to publish some articles of population PK/PD work
> in several clinical pharmacology journals in the past, and I was so
> confident for just a poster presentation in ASCO. However, the judgment
> was “publication only”, i.e. just presentation in online =
but no poster
> presentation and no official record of publication officially.
>
>
>
> So, my question is whether pharmacometrics work is difficult to be picked
> up in ASCO presentation. Or, was my work evaluated to have no worth to b=
e
> presented even in poster session because the pharmacometrics works
> presented in ASCO are having very high level?
>
>
>
> I have never visited ASCO before, and I just want to hear opinions about
> how much of importance is considered for pharmacometrics work in ASCO.
>
>
>
> Thanks a lot in advance for your comments/thoughts.
>
>
>
> Best regards,
>
> Naoto Hayashi
>
>
>
>
>
> This message and any attachment are confidential and may be privileged or
> otherwise protected from disclosure. If you are not the intended recipien=
t,
> you must not copy this message or attachment or disclose the contents to
> any other person. If you have received this transmission in error, please
> notify the sender immediately and delete the message and any attachment
> from your system. Merck KGaA, Darmstadt, Germany and any of its
> subsidiaries do not accept liability for any omissions or errors in this
> message which may arise as a result of E-Mail-transmission or for damages
> resulting from any unauthorized changes of the content of this message an=
d
> any attachment thereto. Merck KGaA, Darmstadt, Germany and any of its
> subsidiaries do not guarantee that this message is free of viruses and do=
es
> not accept liability for any damages caused by any virus transmitted
> therewith.
>
>
>
> Click http://www.merckgroup.com/disclaimer to access the German, French,
> Spanish and Portuguese versions of this disclaimer.
>

Received on Wed Apr 06 2016 - 05:01:21 EDT

This archive was generated by hypermail 2.3.0 : Fri Sep 27 2019 - 16:49:46 EDT